Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cytosorbents Corp CTSO

Healthcare Medical Devices
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive... see more

Recent & Breaking News (NDAQ:CTSO)

CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

PR Newswire October 7, 2021

CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19

PR Newswire September 14, 2021

CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies

PR Newswire September 13, 2021

CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR(TM) Antithrombotic Removal System During Urgent Cardiothoracic Surgery

PR Newswire September 10, 2021

CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

PR Newswire September 8, 2021

Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

PR Newswire September 1, 2021

CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb(TM) Adsorber and PerLife(TM) Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress

PR Newswire August 30, 2021

CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress

PR Newswire September 26, 2017

Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®

PR Newswire September 25, 2017

World Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony

PR Newswire September 14, 2017

Aferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation

PR Newswire September 11, 2017

CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference

PR Newswire September 6, 2017

CytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium

PR Newswire September 5, 2017

CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients

PR Newswire August 14, 2017

CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017

PR Newswire August 7, 2017

Investor Network: CytoSorbents Corporation to Host Earnings Call

Accesswire August 7, 2017

Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®

PR Newswire Europe Non Regulatory August 2, 2017

CytoSorbents to Report Q2 2017 Operating and Financial Results

PR Newswire August 1, 2017

CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR

PR Newswire July 17, 2017

CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma

PR Newswire July 13, 2017